Dr. Jeffrey Sosman, MD

• Medical Oncology

• Hematology

• Hematology & Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• University Of Wisconsin Hospital

  Fellowship Hospital

• University Of Chicago|university Of Wisconsin-madison

  Residency Hospital, 1985

• University Of Chicago|university Of Chicago Medical Center

  Internship Hospital, 1982

• Albert Einstein College Of Medicine

  Medical School, 1981

• English

• Dutch

• Endocrine side effects of immune checkpoint inhibitors, 2023-05-11

• Targeted next generation sequencing identifies markers of response to PD-1 blockade, 2016-09-26

• Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials, 2016-11-11

• Two Phase II Trials of the Novel Akt Inhibitor Perifosine in Patients with Advanced Renal Cell Carcinoma Following Progression on VEGF-Targeted Therapy, 2012-06-06

• The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma, 2019-03-27

• Melanoma whole exome sequencing identifiesV600EB-RAFamplification-mediated acquired B-RAF inhibitor resistance, 2012-03-06

• The "Great Debate” at Melanoma Bridge 2020: December, 5th, 2020, 2021-04-07

• Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial, 2015-06-23

• Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation, 2010-11-24

• Multiple gastrointestinal polyps in patients treated with BRAF inhibitors, 2015-07-22

• PreexistingMEK1Exon 3 Mutations inV600E/KBRAFMelanomas Do Not Confer Resistance to BRAF Inhibitors, 2012-04-01

• Innovations and Challenges in Renal Cancer: Summary Statement From the Third Cambridge Conference, 2009-05-15

• Improved methods for RNAseq-based alternative splicing analysis, 2021-05-24

• Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance, 2015-09-10

• A multicenter phase I study evaluating dual PI3K and BRAF inhibition with PX-866 and vemurafenib in patients with advanced BRAF V600 mutant solid tumors, 2017-10-19

• Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction, 2016-10-18

• Recurrent tumor cell-intrinsic and -extrinsic alterations during MAPKi-induced melanoma regression and early adaptation, 2017-09-01

• Contribution of Beta-HPV Infection and UV-Damage to Rapid-onset Cutaneous Squamous Cell Carcinoma during BRAF-inhibition Therapy, 2015-02-27

• RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E), 2011-11-23

• Infiltrating T cells increase IDO1 expression in glioblastoma and contribute to decreased patient survival, 2017-07-27

• Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies, 2015-02-06

• High response rate to PD-1 blockade in desmoplastic melanomas, 2018-01-10